Nuclear Interactor of ARF and Mdm2 (NIAM, gene designation Tbrg1) is a largely unstudied inhibitor of cell proliferation that helps maintain chromosomal stability. It is a novel activator of the ARF-Mdm2-Tip60-p53 tumor suppressor pathway as well as other undefined pathways important for genome maintenance. To examine its predicted role as a tumor suppressor, we generated NIAM mutant (NIAM m/m ) mice homozygous for a b-galactosidase expressing gene-trap cassette in the endogenous gene. The mutant mice expressed significantly lower levels of NIAM protein in tissues compared to wild-type animals. Fifty percent of aged NIAM deficient mice (14 to 21 months) developed proliferative lesions, including a uterine hemangioma, pulmonary papillary adenoma, and a Harderian gland adenoma. No age-matched wild-type or NIAM +/m heterozygous animals developed lesions. In the spleen, NIAM m/m mice had prominent white pulp expansion which correlated with enhanced increased reactive lymphoid hyperplasia and evidence of systemic inflammation. Notably, 17% of NIAM mutant mice had splenic white pulp features indicating early B-cell lymphoma. This correlated with selective expansion of marginal zone B cells in the spleens of younger, tumor-free NIAM-deficient mice. Unexpectedly, basal p53 expression and activity was largely unaffected by NIAM loss in isolated splenic B cells. In sum, NIAM down-regulation in vivo results in a significant predisposition to developing benign tumors or early stage cancers. These mice represent an outstanding platform for dissecting NIAM's role in tumorigenesis and various anti-cancer pathways, including p53 signaling.
Introduction
The p53 tumor suppressor forms the core of an extensive signaling network that protects cells against genomic instability and neoplastic transformation in response to genotoxic insults [1] [2] [3] . Once activated, p53 transactivates or represses a wide array of genes that cause cell cycle arrest, promote DNA repair, restrict metabolism or kill irreparably damaged cells, among other anticancer activities [4] . Loss of p53 function occurs in the vast majority of human cancers, if not all, due to TP53 gene mutation or alteration of its many regulators and targets [2, 5] . Mouse models that lack p53 or express naturally occurring p53 mutants are highly tumor prone and develop the broad range of malignancies found in humans with impaired p53 signaling [6] [7] [8] . Understanding how p53 activity is controlled, and the importance of its regulators in tumor biology, has been a top priority in cancer research for more than two decades [1] [2] [3] 9] . NIAM (Nuclear Interactor of ARF and Mdm2, also called Tbrg1) is a new p53 regulator and anti-proliferative factor whose role in cancer is not yet defined [10] [11] [12] [13] . Mechanistically, it engages the p53 pathway at multiple levels. First, NIAM promotes the relocalization of ARF (Alternative Reading Frame protein), a major activator of p53 [14] , from nucleoli into the nucleoplasm where it is more effective at activating p53 [10, 15, 16] . Second, NIAM binds to Mdm2, the primary antagonist of p53 [17] , and reduces the formation of p53-Mdm2 complexes [10, 12] . As such, NIAM impairs Mdm2-mediated polyubiquitylation and proteasomal degradation of p53, thereby stabilizing and activating p53 signaling [12] . Third, NIAM is a chromatin-bound protein that associates with the histone acetyltransferase, Tip60 (Tat-interacting protein of 60 kDa) [12] , which is essential for p53-dependent cell cycle arrest and death [18] [19] [20] . Tip60 knockdown studies demonstrated that it contributes to NIAM-mediated p53 activation, revealing that NIAM induces p53 activity through multiple mechanisms involving Tip60 association as well as Mdm2 inhibition [12] . Notably, like p53 and Tip60, NIAM is normally kept at low expression levels in cells by Mdm2-dependent ubiquitylation [10] .
The interplay of NIAM with p53 and its established partners (ARF, Mdm2 and Tip60), all of which are frequently disrupted in human cancers [3, 14, 17, 21, 22] , suggests NIAM may have tumor suppressive activity. That idea is supported by in silico evidence from microarray databases suggesting significant down-regulation of NIAM mRNA levels in many advanced human cancers [23, 24] . Interestingly, NIAM can act independently of ARF-Mdm2-p53 signaling. It can inhibit proliferation in cells lacking ARF, Mdm2 and/or p53, and its depletion in ARF/Mdm2/p53-null mouse embryo fibroblasts results in chromosomal instability [10] . These findings imply that NIAM plays an important role in other anticancer pathways outside of the ARF-Mdm2-p53 tumor suppressor pathway.
Here, we describe the generation and initial characterization of the first NIAM mutant mouse model. These animals have hypomorphic NIAM alleles that result in greatly impaired expression of NIAM protein in tissues, similar to what may occur in human malignancies in which its mRNA expression is downregulated. Spontaneous tumor formation was assessed and NIAM down-regulation found to increase tumor susceptibility in aged animals. B-cell lymphoma was among the tumors identified and this correlated with a marked expansion of splenic marginal zone B cells in young, tumor-free NIAM-deficient mice. Interestingly, p53 inactivation in B cells promotes splenic marginal zone B cell expansion and B-cell lymphoma [25, 26] , implicating impaired p53 function in the NIAM knockout phenotype. At least under nonstressed conditions, however, splenic B cells from young NIAMdeficient mice showed no significant effect on basal p53 activity. We suggest that the NIAM mutant mice described in this study represent a unique model of B-cell lymphoma that should help resolve NIAM's biological role in p53 signaling and other cancer pathways.
Results

Decreased NIAM mRNA expression in human tumors
It is well established that ARF-Mdm2-Tip60-p53 signaling plays a dominant role in carcinogenesis [1] [2] [3] 17, 21, 27] . Since NIAM has important roles in regulating this pathway, we probed various online databases for the most recent information on NIAM alterations in human cancers. A previous analysis of the ONCOMINE microarray database in 2007 suggested that NIAM mRNA expression is down-regulated in multiple advanced human cancers [10] . The addition of large amounts of microarray results to ONCOMINE since that time only strengthens that conclusion, once again suggesting significant reduction of NIAM mRNA levels in many cancers including lung, breast, brain, prostate, and B-cell lymphoma ( Table 1) . Recent RNA sequencing data from The Cancer Genome Atlas (TCGA) project is now available for certain cancers and verifies that there is a marked decrease in NIAM (gene name Tbrg1) mRNA levels in human lung, liver, bladder, and breast cancers as compared to paired, normal tissues (Fig. 1 ). These data demonstrate that NIAM expression is reduced in many different types of human malignancies, consistent with the prediction that it plays an important role in inhibiting tumorigenesis.
Generation of NIAM-deficient mice
A NIAM gene targeting construct was inserted between exon 1 (which contains the ATG start site) and exon 2 in C57BL/6N embryonic stem cells by the Knockout Mouse Project (KOMP) (Fig. 2A) . The cassette contains a poly (A) adenylation site, a neomycin resistance gene (Neo), and b-galactosidase trap for tracking normal NIAM expression patterns in tissues. It also contains FRT sites for removal of neomycin and b-galactosidase cassettes by flippase, which would restore normal gene function of NIAM. Two intronic LoxP sites enable conditional deletion of exon 2 using Cre-expressing mice should the cassette not lead to sufficient loss of the NIAM gene. This construct is predicted to interfere with splicing or, at minimum, generate a severely truncated chimeric protein containing only 48 N-terminal residues of NIAM. We obtained chimeric mice expressing the mutant (m) NIAM allele from KOMP and generated NIAM heterozygous (+/m) mice by crossing them to C57BL/6N breeders. After obtaining germline transmission, we interbred heterozygous mice to obtain homozygous offspring (m/m) (Fig. 2B) . Heterozygous mouse matings (n = 31) produced litter sizes between 1 to 9 pups (avg = 5.58). The genotype (+/+, +/m, m/m) was determined for 173 mice and the expected Mendelian ratios of 1:2:1 were not met (p = 0.0035, using the x 2 -test) (Fig. 2C) . The number of heterozygous NIAM +/m and homozygous NIAM m/m mice was higher than expected, possibly suggesting that NIAM loss may provide a selective advantage during embryogenesis. The NIAM m/m mice also successfully mated and produced offspring demonstrating no crucial effects of NIAM on fertility and viability.
To determine if the gene-trap cassette effectively interfered with NIAM expression, mouse tissues from each genotype were obtained and assessed for levels of NIAM protein. NIAM expression was greatly diminished although some level of expression remained in all NIAM m/m mouse tissues examined, demonstrating that these animals have hypomorphic NIAM alleles (Fig. 3) . Effective down-regulation of NIAM expression was observed in the bladder, lung, pancreas and spleen of homozygous m/m mice. By comparison, protein extracts from the brain (Fig 3) and testes (not shown) of the NIAM m/m mice showed decreased yet substantial remaining expression of NIAM as compared to wildtype mice. Interestingly, many bands for NIAM protein were detected in some tissues, such as brain, consistent with database predictions for the existence of numerous alternative transcripts of NIAM. Tissues were also examined for expression of p53, Mdm2 and p21. NIAM would be predicted to reduce their levels; however, we did not expect to detect significant changes in their expression since p53 signaling is generally kept off in normal tissues under non-stressed conditions. Indeed, basal expression of all three factors was low, and in some cases undetectable, in whole tissue lysates with no consistent differences observed between NIAM m/m and wild-type mice (data not shown). Immunohistochemical analyses of tissues to identify cell-specific changes in naïve versus stressed mice exposed to p53 activating stimuli (e.g., irradiation) should more effectively reveal effects of NIAM downregulation on the p53 pathway in vivo. Overall, a significant decrease in NIAM expression was observed in NIAM +/m and NIAM m/m mice relative to wild-type controls, indicating these animals are a useful model for examining the biological effects of reduced NIAM expression in vivo.
Loss of NIAM in vivo promotes spontaneous tumor formation NIAM m/m mice grow to adulthood and normal size, are fertile, and are externally indistinguishable from wild-type mice. Moreover, full pathological examination of young NIAM mutant animals at approximately 8 weeks of age showed no apparent tissue abnormalities, suggesting that tissue development is unaffected by NIAM deficiency. However, NIAM carries out a variety of anti-cancer activities in cultured cells [10, 12] and our database analyses ( Table 1 and Fig. 1 ) indicate its expression is downregulated in many human cancers, suggesting it may normally prevent tumor development. Thus, we assessed aged mice of all three NIAM genotypes for spontaneous tumorigenesis. As shown in Table 2 , 50% of NIAM m/m mice developed a neoplastic lesion whereas no wild-type and heterozygous mice of similar age showed obvious signs of tumorigenesis (p = 0.0025, Fisher's exact test). The NIAM m/m mice developed different types of benign tumors including a uterine hemangioma (Fig. 4A) , an early lung papillary adenoma ( Fig. 4B) , and a Harderian gland adenoma (Fig. 4C) . In addition, a focus of cellular alteration (FCA) was seen in the liver of one NIAM m/m mouse ( Fig. 4D) , a precancerous lesion seen in other mouse models [28] . These histopathological findings suggest that NIAM normally suppresses neoplasia.
Inflammation and early B-cell lymphoma develop in
A prominent finding within the cohort was the pathological changes in the spleens of older NIAM mutant mice, which were significantly increased in size compared to wild-type and heterozygous mouse spleens (p ,0.05) (Fig. 5A ). Hematoxylin and Eosin (H&E) staining showed that NIAM deficiency led to a significant expansion of the splenic white pulp compared to control age matched cohorts (Fig. 5B, C) . These white pulp changes in NIAM m/m mice were often due to reactive hyperplasia. This, along with perivascular lymphoid aggregates in various visceral organ, was consistent with systemic inflammation in mice [29] . In addition, one NIAM m/m mouse had severe diffuse eosinophilic crystalline pneumonia (ECP) whereas only one control had minor localized ECP disease (Fig. 5D ). ECP may be seen in certain strains of mice including those with immunodeficiency and Th2 prone inflammatory environments [30, 31] . Altogether, these data suggest that NIAM mutant mice have a proinflammatory phenotype. Additionally, two of the twelve (17%) NIAM m/m mice developed early B-cell lymphoma. Their spleens had multifocal loss of the white pulp architecture (e.g. small lymphocytes, germinal centers and tingible body macrophages) with replacement by highly mitotic centrocytic and centroblastic cells (Fig. 5E ) [32] . When considered with the development of various benign neoplasms in other NIAM m/m animals, these results indicate that NIAM expression is required to prevent spontaneous tumorigenesis.
Marginal zone B cells are increased in NIAM m/m mice
Since aged NIAM m/m mice have enlarged spleens and some develop B-cell lymphoma, we evaluated B cell development in younger, tumor-free mice (6 months of age, 3 of each NIAM genotype) to identify potential pre-malignant changes that could give rise to B-cell tumors. Analysis of B cell development in the bone marrow of NIAM m/m mice revealed no alterations compared to wild-type control animals (Fig. S1) . Specifically, there were no significant differences in the frequency of pro/pre (B220+IgM-, p = 0.4783), immature (B220+IgM+, p = 0.7693) or mature (B220 hi IgM+, p = 0.8048) B cells. Analysis of B cells from the spleen likewise showed no difference in the frequency of transitional (CD21 lo /CD23-) or follicular (CD21+/CD23+) B cells ( Fig. 6A, B ; p values of 0.5068 and 0.9325, respectively). In contrast, splenic marginal zone B cells (CD21 hi /CD23-) were significantly increased in frequency (p = 0.0281) and number (p = 0.0144) in NIAM m/m mice compared to wild-type controls (Fig. 6) . These results uncover a specific sensitivity of splenic marginal zone B cells to NIAM loss, which may suggest that NIAM normally restricts their proliferation.
Selective expansion of splenic marginal zone B cells also occurs in mice with conditional inactivation of p53 in B cells and it is associated with their development of B-cell lymphomas [25, 26] . Since NIAM is a positive regulator of p53 expression and transcriptional activation [12] , and some NIAM mice developed B-cell lymphoma, we wondered if the B cell phenotype in NIAM m/ m mice could be associated with reduced p53 signaling. Therefore, we examined p53 status in LPS-stimulated splenic B cells isolated from five wild-type NIAM +/+ and five mutant NIAM m/m mice. Western analyses showed complete NIAM loss in NIAM m/m cells compared to wild-type B cells (Fig. 7) . We expected NIAM loss would reduce p53 levels and activity, but surprisingly it had no effect on basal expression of p53 or its targets, Mdm2 and p21, in the B cells of most NIAM m/m mice (4 of 5) relative to NIAMpositive B cells (Fig. 7, set A) . These results were seen in B cells isolated from both 8 week and 6 month old mice, suggesting the marginal zone B cell expansion in 6 month old NIAM mutant mice is likely independent of p53. Notably, one NIAM mutant mouse had decreased B cell expression of p53 although this did not correlate with reduced expression of Mdm2 or p21, at least under these stress-free conditions (Fig. 7, set B) . These analyses show that NIAM is not required for basal p53 activity in splenic B cells but may, depending on the context, predispose to p53 downregulation. Additional studies examining p53 stimulation and checkpoint activation following DNA damage or other genotoxic insults in NIAM-deficient B cells are warranted.
Discussion
This study is the first investigation of NIAM function in vivo using newly generated NIAM-deficient mice. A tumor suppressor role for NIAM was anticipated given its ability to activate p53 and other currently undefined anti-cancer pathways involved in growth inhibition and genome maintenance [10, 12] . Consistent with that prediction, reduced NIAM expression in mice yielded a tumor phenotype characterized by the development of both benign and cancerous lesions, including early B-cell lymphoma. No neoplasms developed in similarly aged heterozygote or wildtype controls, strongly suggesting that tumor formation was due to NIAM loss. It is noteworthy that systemic inflammation was seen in multiple mice as that often precedes tumorigenesis. Although mice from each genotype (+/+, +/m, m/m) in our cohort showed signs of heightened inflammation, only the NIAM m/m animals develop lesions. Thus, it is possible that reduced NIAM expression may accelerate or exacerbate the tumor promoting effects of a chronic inflammatory response.
The development of B-cell lymphoma in NIAM m/m mice is consistent with several observations. First, microarray analyses suggest that NIAM mRNA levels are significantly reduced in human B-cell lymphomas [33] [34] [35] [36] [37] . Second, NIAM's functional partners, ARF, Mdm2, and p53 each play a critical role in that disease. ARF and p53 are commonly inactivated whereas Mdm2 is overexpressed in a majority of B-cell lymphomas in patients [38] [39] [40] , and genetically engineered mice that mimic those alterations effectively model the disease [41] [42] [43] . Finally, NIAM is a growth inhibitor whose activation of p53 in cultured cells results in induction of p21 (CDKN1A/Waf1/Cip1) [10, 12] , a key transcriptional target of p53 [44, 45] . Others previously showed that a significant fraction (14%) of tumors that develop in p21 knockout mice are B-cell lymphomas [46] , which is similar in incidence (17%) to the B-cell lymphomas arising in NIAM m/m mice. Our data show that NIAM contributes to tumor suppression but to a lesser extent than p53 or ARF. Half of NIAM m/m mice developed benign and early cancerous lesions at an average age of 16.5 months (66 weeks). By comparison, mice lacking p53 in all tissues develop a range of malignancies (mainly T-cell lymphomas and sarcomas) with full penetrance at approximately 5 months of age [6, 7] . Less pronounced in vivo effects are observed for disruption of p53 regulators and targets relative to loss of p53 itself [2] . For example, animals lacking ARF, a major positive regulator of p53, develop tumors at a slower rate (,10 months average age) than p53-null mice [47, 48] . Among p53 targets, loss of PUMA causes no increased susceptibility to tumorigenesis [49] while deletion of p21 yields a moderate tumor phenotype [46] . Specifically, p21-null animals develop tumors at an average age of 16 months and with reduced incidence (27% in females, 55% in males) compared to mice lacking p53. Thus, a milder tumor phenotype for NIAM m/m mice is not surprising since it represents just one of many p53 regulators [1, 3] .
We currently know very little about the normal physiological or pathological signals that control NIAM expression and where its function is required. The expression of b-galactosidase in these mutant mice will provide an excellent surrogate for tracking normal patterns of NIAM expression during development, in particular tissue and cell types, and in response to different stimuli. The interplay between NIAM, p53, and ARF, as well as NIAM's regulation of p21 expression, may be instructive. For instance, loss of each factor (p53, ARF, or p21) is associated with impaired stem cell maintenance and renewal for a variety of cellular lineages, including hematopoietic and neuronal cells, suggesting a possible contribution by NIAM to those processes and cell types [50] [51] [52] . Similarly, one of the most significant cellular stresses that stimulate p53 activity is DNA damage [1] . We recently found that treatment of MCF10A mammary epithelial cells causes NIAM protein upregulation (Fig. S2) , implying a role for NIAM in the DNA damage response. The importance of NIAM to p53 activation and maintenance of DNA integrity in different tissues in response to DNA damage or other diverse stimuli may now be evaluated in an in vivo context.
A link between NIAM and p53 in B cell development and lymphoma was strongly suggested by findings that mice lacking those genes each display splenic marginal zone B cell expansion and B-cell lymphoma ( [25, 26] and this study). Yet NIAM loss had minimal effects on basal p53 expression and activity in B cells from young animals, with just one of five NIAM m/m mice displaying lower p53 levels. That unexpected result suggests the splenic marginal zone B cell enrichment in young NIAM m/m mice is independent of p53. However, it remains to be determined if p53 function in response to DNA damage or other cellular stresses is diminished in NIAM m/m cells and contributes to tumor development in older animals. Indeed, it is conceivable that lower basal p53 expression in splenic B cells observed in some NIAM m/m mice impairs stress-induced p53 signaling and checkpoint activation, ultimately fostering B-cell lymphomagenesis in aging mice. Future studies will assess that possibility.
Crosses between NIAM mutant mice with other genetic models of cancer will be instrumental in determining NIAM's contribution to p53 signaling as well as other cancer pathways. In that regard, in vivo studies should help resolve the biological relevance of NIAM's association with the ARF tumor suppressor [10] [11] [12] . Initial studies showed NIAM is capable of mobilizing ARF into the nucleoplasm [10] , where ARF is known to more effectively bind Mdm2 and activate p53 [15, 16] , yet NIAM and ARF can nonetheless act independent of each other to transiently activate p53 [10, 12] . It is possible that NIAM's inhibition of Mdm2 and association with Tip60 may help sustain ARF-p53 signaling and promote senescence in cells following DNA damage or oncogene activation. If so, this would represent an important anti-cancer function since p53-mediated cellular senescence (induced by ARF or other mechanisms) is thought to play a pivotal role in tumor suppression [53] [54] [55] [56] .
Earlier work on NIAM and much of this Discussion has revolved around the idea that NIAM would prevent tumorigenesis, at least in part, through its effects on p53. However, it is likely that NIAM has significant anti-cancer functions in vivo that are independent of p53. One reason is that NIAM can inhibit proliferation and promote chromosomal stability independent of ARF, Mdm2, and p53, indicating it acts in other important pathways relevant to maintaining genomic stability [10] . Moreover, in this study basal p53 expression in splenic B cells was unchanged by NIAM loss in most animals. One factor besides p53 that could contribute to the tumor phenotype in NIAM m/m mice is transforming growth factor beta 1 (TGF-b1). NIAM was originally identified as a TGF-b1 responsive gene [13] and we previously found it is induced in TGF-b1-arrested cells [10] . TGF-b1 is a potent inhibitor of proliferation in many cell types (epithelial, endothelial, hematopoietic, etc), but alterations of its signaling components in neoplastic cells ultimately causes it to drive proliferation and cancer progression [57, 58] . If NIAM is an effector of TGF-b signaling, its down-regulation in NIAM m/m mice may diminish the anti-proliferative activities of the pathway and consequently enhance its tumor-promoting effects.
Another factor of interest is the nuclear transcription factor, NFkappa B. NF-kB was originally identified in B cells, contributes to marginal zone B cell formation, and is often constitutively activated in numerous inflammatory conditions and human cancers, including B cell lymphomas [59, 60] . NF-kB is activated by a multitude of stimuli and cross-talks with many essential molecules (e.g., p53 and STAT3) and complex signaling pathways (including TGF-b) that control inflammation, cell survival and cell proliferation, among other key biological processes. The enrichment of marginal zone B cells as well as progressive expansion of splenic white pulp and development of B-cell lymphomas in NIAM mutant mice supports the prediction that NF-kB signaling may be hyper-activated when NIAM is down-regulated.
Overall, our data show that NIAM deficiency is associated with a proinflammatory phenotype and facilitates spontaneous tumorigenesis. Based on the literature, we speculate that the marginal zone B cell expansion in NIAM mutant mice is intimately related to their development of systemic inflammation [61] and B cell lymphomagenesis [25, 26] . We also predict that NIAM, as a regulator of ARF-Mdm2-Tip60-p53 signaling and other undefined pathways affecting maintenance of chromosomal stability, normally cooperates with multiple anti-cancer pathways to suppress tumor development. The NIAM m/m mice described here are an outstanding model to explore those concepts.
Materials and Methods
Animal Husbandry and Ethics Statement
Mice were housed in the University of Iowa Animal Care barrier facility. Mice were kept in rooms with a 12 hour light-dark cycle and free access to water and food. All mouse experiments were conducted according to protocols approved by the University of Iowa Institutional Animal Care and Use Committee (protocol#1204079). All efforts were made to minimize suffering. Mice were euthanized using carbon dioxide inhalation.
Generation of NIAM Mutant Mice
The Knockout Mouse Project (KOMP) generated male chimeras by injecting embryonic stem cells containing a NIAM (TBRG1) allele with a b-galactosidase cassette and LoxP sites around Exon2 into C57BL/6 blastocysts (www.komp.org, Project ID: CSD41510). Chimeric mice were then bred with C57BL/6N females to obtain germline transmission of the mutant TBRG1 allele. To confirm mouse genotypes, the REDExtract-N-Amp Tissue PCR Kit (Sigma Aldrich, XNAT-100RXN) was used to isolate DNA from mouse tails and to perform PCR. PCR genotyping primers were: Primer a: 59-GGTCAAAGCTG-TAAGCATAGAGAGTC -39; Primer b: 59-CTTGAGG-CTCCTTTCTGGTG -39; Primer c: 59-CCAACTGACCT-TGGGCAAGAACAT -39. PCR reactions consisted of 2 mL DNA added to 5 ml RedExtract PCR Master Mix (Sigma Aldrich), 0.8 ml of each primer and 0.6 mL PCR grade water to a total reaction volume of 10 mL. PCR was performed as follows: 95uC for 5 min, 35 cycles of 95uC for 1 min, annealing of primers at 54uC for 1 min, and extension at 72uC for 1.5 min on a PCR Sprint thermal cycler (Thermo Scientific Hybaid).
Database Analyses
The Cancer Genome Atlas Pan-Cancer analysis project's individual RNAseq datasets were downloaded from the UCSC Cancer Genome Browser (https://genome-cancer.ucsc.edu/). The UCSC Cancer Browser Team utilized level 3 TCGA RNAseq datasets (available at https://tcga-data.nci.nih.gov/tcga/), log2(x+ 1) transformed, and renormalized to the expression of all available TCGA cancer cohorts. PanCan normalized, log2(x+1) expression for available paired normal and primary tumor samples were compared for each TCGA cancer cohort utilizing an unpaired Welch's T-test.
Protein Analyses in Mouse Tissues
Mouse tissues were isolated, flash frozen in liquid nitrogen, and crushed into a powder by mortar and pestle. Tissues were lysed All p values were calculated using unpaired, two-tailed Student's T tests. doi:10.1371/journal.pone.0112126.g006 Figure 7 . NIAM is not required for basal p53 activity in splenic B cells. Splenic B cells from young, tumor-free wild-type NIAM +/+ or NIAM m/m homozygous mutant mice were isolated and expression of endogenous NIAM, p53, Mdm2 and p21 proteins was assessed by western blotting. Relative levels of p53, Mdm2 and p21 (normalized to GAPDH loading and compared to the untreated, wild-type control sample) were determined following quantification of bands using Image J. Representative results from 4 of 5 pairs of mice (both 8 week and 6 months of age) are shown in Set A, while Set B shows data for one pair of 6 month old mice. Set A and B samples were analyzed on separate gels, and lanes within each set were spliced together from the same autoradiogram for image clarity. doi:10.1371/journal.pone.0112126.g007
with RIPA buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, 0.5% Sodium deoxycholate) supplemented with 1 mM NaF, protease inhibitor cocktail (Sigma, P8340), phosphatase inhibitor cocktail (Sigma, P0044), and 30 mM phenylmethylsulfonyl fluoride for 1 hour on ice. After brief sonication (265s pulses), protein lysates were centrifuged at 14,000 rpm for 15 min at 4uC. The concentration of protein for each tissue was assessed by BCA assay (Pierce, Rockford, IL). Equivalent amounts of total cellular protein was loaded and separated by SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membranes (Millipore), and analyzed by immunoblotting. Proteins were detected on membranes by ECL (Amersham Biosciences) with antibodies against NIAM (rabbit polyclonal antibody at 1.5 mg/ml [10] and mouse monoclonal antibody [clone 11E12] at 1:5 dilution [62] ) and c-tubulin (Sigma, T6557, mouse monoclonal antibody, 1:10,000).
Primary B Cell Analyses
Bone marrow and spleens were harvested from wild-type and NIAM mutant mice (three 6 month old littermate males per genotype) and minced between frosted glass slides to liberate cells. ACK lysis (Lonza, Radnor, PA) was used to lyse red blood cells. For flow cytometric analyses of B cells, one million lymphocytes were washed and resuspended in staining buffer that consisted of balanced salt solution, 5% bovine calf serum and 0.1% sodium azide. Non-specific binding of antibody was blocked using 10 ml rat serum (Jackson Immunoresearch, West Grove, PA) and 10 mg 2.4G2 (BioXCell, West Lebanon, NH). Cells were then incubated on wet ice in the dark with antibodies to B220-PE-Cy7 (6B2, eBioscience, San Diego, CA), CD23-PE (B3B4, eBioscience), CD21-APC (7G6, BD Biosciences, San Jose, CA), and IgM-FITC (RMM-1, Biolegend, San Diego, CA). Samples were run on a BD FACSCANTO II instrument (Becton Dickinson, San Jose, CA) and data were analyzed using FlowJo (Tree Star, Ashland, OR).
For analyses of p53, B cells were isolated from spleens of 6 month and 8 week old wild-type and NIAM mutant mice using B220 micro beads (Miltenvi Biotec, San Diego, CA) according to manufacturer's specifications. Cells were plated at 5610 5 c/ml in B-cell media (RPMI, 10% fetal calf serum, 2 mM Glutamine, 1 mM Sodium Pyruvate, 0.055 mM b-mercaptoethanol and 100 units/ml of penicillin with 100 mg/ml streptomycin) supplemented with LPS (Sigma) at 20 mg/ml to maintain viability. After overnight incubation at 37uC, 5% CO 2, cells were harvested and lysed directly in 16 SDS-PAGE sample buffer. Samples (1610 6 cell equivalents) were subjected to SDS-PAGE and protein expression examined by western blotting as described above using antibodies to p53 (Santa Cruz, Sc-6243 [FL-393] rabbit polyclonal, 1:200), Mdm2 (2A10 mouse monoclonal, 1:10), p21 (Calbiochem, PC55 [Ab-5], rabbit polyclonal, 2 mg/ml), and GAPDH (Abcam, Ab8245, mouse monoclonal, 1:20,000).
Mouse Necropsy and Histopathological Analyses
Individual organs were harvested from mice euthanized by CO 2 asphyxiation. A total of 28 mice (8 NIAM +/+ , 8 NIAM +/m and 12 NIAM m/m ) between the ages of 14 to 21 months were subjected to pathological examination. Organs assessed by macroscopic and histopathological analyses included pancreas, liver, spleen, gastrointestinal tract, reproductive tract for males and females, kidney, urinary bladder, lung, heart, head sections (e.g., eyes, nasal cavity, etc), and sagittal section of the brain (cerebellum, cerebrum and brain stem). Organ weights (e.g., spleen and liver) were collected and then tissues were formalin fixed and paraffin embedded. Tissue sections (,4 mm) were made from paraffin blocks and stained with hematoxylin and eosin (H&E). Mouse tissues were analyzed and reviewed for abnormal findings by a pathologist. Quantification of the white pulp of individual mouse spleens stained with H&E was measured by Image J software. The splenic white pulp was evaluated as a percentage of the total splenic area in tissue sections. 
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